Telo Genomics Announces Expanded Partnership with Trusted Health Advisors
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that, further to its engagement with Trusted Health Advisors ("THA"), as disclosed in a news release dated January 30, 2024, the Company has expanded and extended its agreement (the "Agreement") with THA. Under the new Agreement, THA will further support the partnering and commercialization of Telo's diagnostic technologies over a six-month...
2025-02-27 8:30 AM EST
Telo Genomics Closes Oversubscribed $2.5 Million Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release dated December 12, 2024, it has closed an over-subscribed, non-brokered private placement of 25,459,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $2,545,900 (the "Offering"). Each Unit consists of one common share of the Company (a "Common Share") and one non-transferable...
2024-12-23 4:00 PM EST
Telo Genomics Announces Private Placement for up to $2 Million
Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.10 per Unit for gross proceeds of up to $2,000,000 (the "Offering"). Each Unit will consist of one common share of the Company (a "Common Share") and one non-transferable common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to...
2024-12-12 8:45 AM EST
Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)
Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that its application to the IPON program (Intellectual Property Ontario) was approved. The IPON program leverages the innovation of Ontario enterprises in securing and...
2024-11-19 8:45 AM EST
Telo Genomics Expands its Strategic Collaboration with Mayo Clinic
Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US. The amendment is an extension of the Telo Genomics relationship with Mayo Clinic to include their...
2024-10-30 8:45 AM EDT
Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has presented the most recent performance results of its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the recent International Myeloma...
2024-10-22 8:45 AM EDT
Telo Genomics Assessing MRD Status in TELO-DMRD Study
Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study....
2024-09-10 8:45 AM EDT
Telo Genomics Receives CLIA Certification
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the US Centres of Medicare & Medicaid Services (CMS) which regulates the medical laboratories in the USA, has awarded Telo its Clinical Laboratory Improvement Amendment...
2024-08-13 8:45 AM EDT
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP
Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the College of American Pathologists (CAP) has recently accepted Telo Genomics' submission to add Telo's test for smoldering multiple myeloma (SMM), TeloViewSMM, as a...
2024-06-18 8:45 AM EDT
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024
Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place in Chicago, USA between May 30-June 4, 2024. The...
2024-06-12 8:45 AM EDT
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology
Toronto, Ontario--(Newsfile Corp. - May 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology, is thrilled to announce that the manuscript titled, "Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma" was accepted for publication in the American Journal of Hematology....
2024-05-30 8:45 AM EDT
Telo Genomics and Emery Pharma Announce Collaboration
Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology is pleased to announce that the Company has signed a collaboration agreement with Emery Pharma ("Emery"). Emery is a full-service contract research organization (CRO) offering biologic drug development support and analytical...
2024-05-15 8:45 AM EDT
Telo Genomics Receives Accreditation from College of American Pathologists
Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to TELO's laboratory at the MaRS Center in Toronto, Canada; this is based...
2024-04-10 8:45 AM EDT
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial
Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that patient recruitment for its minimal residual disease ("MRD") clinical trial has been initiated, with several patient samples received and processed to date. Also, due to...
2024-04-02 8:45 AM EDT
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treated patients. The study is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. The trial is listed on the website of the National Library of Medicine...
2024-02-13 8:45 AM EST
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has engaged Trusted Health Advisors (THA), a market leader specialized in guiding commercialization programs of innovative diagnostics products in the USA. THA will work with Telo's team to refine and accelerate Telo's go-to-market and partnership deployment plan, to facilitate the implementation of Telo's biomarker services for basic...
2024-01-30 8:45 AM EST
Telo Genomics Gears up for American Society of Hematology Conference
Toronto, Ontario--(Newsfile Corp. - December 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, looks forward to attending the American Society of Hematology (ASH) annual meeting in San Diego this week. The Company will present the repeatability analytical validation data of its lead product TeloViewSMM, while interacting with a global group of physicians and...
2023-12-06 8:45 AM EST
Telo Genomics Launches Physician Experience Program in the United States
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, is excited to announce the initiation of their Physician Experience Program - SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation). SMART is an observational study intended for cancer treating physicians and their staff in the US to gain experience...
2023-11-16 9:15 AM EST
Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists
Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A), (the "Company" or "Telo"), a biotech company pioneering the most comprehensive A.I. based genomic medical testing, is excited to announce that the College of American Pathologists (CAP) Accreditation Office has informed the company that its certification application has been successfully completed. The company may now proceed to an external assessment audit, the final step to...
2023-11-07 8:45 AM EST
American Society of Hematology (ASH) Accepts Validation Data from Telo Genomics for Presentation at Upcoming Annual Meeting
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") announces today that the American Society of Hematology (ASH) has accepted the results of TeloView-SMM technical repeatability validation for presentation at their annual meeting in December of this year. The study was led by Dr. Hans Knecht, MD, Director of the Division of Hematology at McGill University and the Jewish General Hospital, Montreal, Canada. The...
2023-11-01 8:45 AM EDT